TATA Health International Holdings (HKSE:01255) Research & Development: HK$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01255 TATA Health International Holdings Ltd HKSE:01255
22 GF Score
Price HK$2.18
GF Value HK$0.22
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is TATA Health International Holdings Research & Development?

TATA Health International Holdings HKSE:01255 -0.91% 22 Research & Development is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:01255 with a GF Score™ of 22/100 and a GF Value™ of HK$0.22 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. TATA Health International Holdings's Research & Development for the six months ended in Dec. 2025 was HK$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.00 Mil.

TATA Health International Holdings  (HKSE:01255) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

TATA Health International Holdings Research & Development Related Terms

TATA Health International Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for TATA Health International Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TATA Health International Holdings Research & Development Chart

TATA Health International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TATA Health International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:01255
22GF Score
TATA Health International Holdings Ltd HKSE:01255
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TATA Health International Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0.00 Mil mean?
TATA Health International Holdings (HKSE:01255) has a Research & Development of HK$0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on TATA Health International Holdings and its competitors.
Is TATA Health International Holdings' Research & Development too high?
TATA Health International Holdings' current Research & Development is HK$0.00 Mil. Overall, TATA Health International Holdings has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TATA Health International Holdings' Research & Development compare to NKE and DECK?
TATA Health International Holdings' Research & Development of HK$0.00 Mil can be compared against companies in the Manufacturing - Apparel & Accessories industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Manufacturing - Apparel & Accessories company?
A good Research & Development depends on the Manufacturing - Apparel & Accessories industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on TATA Health International Holdings and its competitors. TATA Health International Holdings's current Research & Development is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TATA Health International Holdings stock overvalued right now?
Based on GuruFocus' analysis, TATA Health International Holdings (HKSE:01255) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.22, compared to a current price of HK$2.18 — trading 890.9% above its estimated fair value. The current Research & Development is HK$0.00 Mil. TATA Health International Holdings' overall GF Score™ is 22/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For TATA Health International Holdings (HKSE:01255), the current Research & Development is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TATA Health International Holdings (HKSE:01255) Overvalued in 2026?

Based on GuruFocus' analysis, TATA Health International Holdings stock appears to be overvalued. The current stock price of HK$2.18 is trading 890.9% above its estimated GF Value™ of HK$0.22. GuruFocus considers TATA Health International Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:01255:

  • Research & Development: HK$0.00 Mil
  • GF Value™: HK$0.22 vs. price of HK$2.18 (890.9% above fair value)
  • GF Score™: 22/100 with 8 warning signs

No single metric tells the full story. See the HKSE:01255 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TATA Health International Holdings Business Description

Address 15-33 Kwai Tak Street, Block 2, Flat F-J, 11th Floor, Kwai Tak Industrial Centre, Kwai Chung, New Territories, Hong Kong, HKG
TATA Health International Holdings Ltd is an investment holding company. Through its subsidiaries, the company operates in four segments: Trading of footwear products, Trading of healthcare products, Financial services, and Online medical services. The majority of its revenue comes from the Trading of footwear products. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from Macau.
22GF Score

Get the complete analysis for HKSE:01255

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.18
Price
HK$0.22
GF Value